Product Name: Zanubrutinib CAS NO: 1691249-45-2
Chemical & Physical Properties:
Appearance : White to off-white powder.
Assay : ≥98.0%
Melting point: N/A
Boiling Point: 713.4℃
Flash Point: N/A
Refractive Index: N/A
Vapor Pressure: 0.0mmHg at 25°C
Solubility: Soluble in DMSO, >50 mg/ml in DMSO. Ethanol : < 1 mg/mL (insoluble).
Category: Drug Analogue; Pharmaceutical/API Drug Intermediates;
HS Code: 2933599090
Storage：Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor..
Zanubrutinib (BGB3111) is a potent, selective and orally available Btk inhibitor; displaysmuch more restricted off-target activities against a panel of kinases, including ITK, compared with Ibrutinib. BGB-3111 selectively binds to and inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway.
Our factory manufacture’s (S)-Zanubrutinib , mature technology, stable output, quality assurance.
Inventory Status : In Stock.
We can provide (7S)-4,5,6,7-Tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide COA (certificate of analysis), MOA (Method of Analysis), Pyrazolo(1,5-a)pyrimidine-3-carboxamide,4,5,6,7-tetrahydro-7-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-,(7S)- ROS (Route of synthesis), CAS 1691249-45-2 MSDS (Material Safety Data Sheet) and other support for you !
(±) -Zanubrutinib CAS: 1633350-06-7 (racemic)
(S)-Zanubrutinib CAS: 1691249-45-2 (S-isomer)
(R)-Zanubrutinib CAS:1691249-44-1 (R-isomer)
Zanubrutinib (BGB-3111) is a selective Bruton tyrosine kinase (BTK) inhibitor. In both biochemical and cellular assays, Zanubrutinib demonstrates nanomolar BTK inhibition activity. In several MCL and DLBCL cell lines, Zanubrutinib inhibits BCR aggregation-triggered BTK autophosphorylation, blocks downstream PLC-γ2 signaling, and potently inhibits cell proliferation. In comparison with PCI-32765, Zanubrutinib shows much more restricted off-target activities against a panel of kinases, including ITK.
Zanubrutinib (BGB-3111) induces dose-dependent anti-tumor effects against REC-1 MCL xenografts engrafted either subcutaneously or systemically via tail vein injection in mice. In the subcutaneous xenografts, Zanubrutinib at 2.5 mg/kg BID shows similar activity as PCI-32765 at 50 mg/kg QD. In the systemic model, the median survival of Zanubrutinib 25 mg/kg BID group is significantly longer than those of both PCI-32765 50 mg/kg QD and BID groups. In an ABC-subtype DLBCL (TMD-8) subcutaneous xenograft model, Zanubrutinib also demonstrates better anti-tumor activity than PCI-32765. Preliminary 14-day toxicity study in rats shows that Zanubrutinib is very well tolerated and maximal tolerate dose (MTD) is not reached when it is dosed up to 250 mg/kg/day.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.